首页> Annals of internal medicine> Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.

Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.

导出原文传递

翻译打印收藏纠错

第一作者： Emanuele,Angelucci

第一单位： Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy (E.A.).

作者： Emanuele,Angelucci ^[1] ; Junmin,Li ^[2] ; Peter,Greenberg ^[3] ; Depei,Wu ^[4] ; Ming,Hou ^[5] ; Efreen Horacio,Montano Figueroa ^[6] ; Maria Guadalupe,Rodriguez ^[7] ; Xunwei,Dong ^[8] ; Jagannath,Ghosh ^[8] ; Miguel,Izquierdo ^[9] ; Guillermo,Garcia-Manero ^[10] ; TELESTO Study Investigators

作者单位： Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy (E.A.). ^[1] Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (J.L.). ^[2] Stanford University Medical Center, Stanford, California (P.G.). ^[3] Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China (D.W.). ^[4] Department of Hematology, Qilu Hospital, Shandong University, Jinan, China (M.H.). ^[5] Department of Hematology, Hospital General de México, Mexico City, Mexico (E.H.M.). ^[6] Department of Hematology, Hospital de Especialidades, Centro Médico Nacional La Raza, IMSS, Mexico City, Mexico (M.G.R.). ^[7] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (X.D., J.G.). ^[8] Novartis Pharma AG, Basel, Switzerland (M.I.). ^[9] MD Anderson Cancer Center, University of Texas, Houston, Texas (G.G.). ^[10]